Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penpulimab + anlotinib first-line treatment for advanced or metastatic urothelial carcinoma
ChiCTR2200056732Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Dec 2019
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of penpulimab and anlotinib in transitional cell carcinoma (TCC), sponsored by Chinese PLA General Hospital. Primary endpoints: Objective response rate and Quality of life improvement. Started Dec 2019; status: recruiting.
02
Drugs
penpulimabanlotinib
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on ChiCTR2200056732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056732.